This month’s HCV Advocate newsletter offers a wealth of information about many aspects of hepatitis C. We sincerely hope that you will take advantage of the information in the newsletter and other postings this month. As it is often said (and true): KNOWLEDGE = POWER.
1. HCV Advocate Newsletter: September, 2013
In This Issue:
- Drugs in Development: Phase 3 – Genotype 1 - DAA plus PEG/RBV
Alan Franciscus, Editor-in-Chief—Learn about the likely next standard of care to treat hepatitis C that includes different direct acting antivirals in combination with pegylated interferon plus ribavirin, holding the promise of higher cure rates, less side effects and, for most people, a shorter treatment duration.
Lucinda K. Porter, RN—This month's column by Lucinda features a recap of articles on non-Hodgkin lymphoma, predicting spontaneous resolution of acute hepatitis C, predicting liver cancer, and boceprevir- and telaprevir-induced kidney impairment.
- HEALTHWISE: Hepatitis C and Your DNA
Lucinda K. Porter, RN—This month's column explores DNA and the implications for HCV treatment.
- HCV and Correctional Centers: A Missed Population
Sonya Becker & Juliana Chan, Pharm.D.—This excellent article reviews HCV in prisons, the reasons for the high prevalence, transmission/prevention and why this information is important for the public health of our society.
- The Other Forgotten Hepatitis B Minority—African-Americans
Christine M. Kukka—Christine M. Kukka discusses the high prevalence of HBV in African Americans and why it is so important that we step up and test, manage and treat African Amercians.
2. HBV Journal Review by Christine Kukka —In this month's column Chris reviews the following studies that will help you understand the complexities of hepatitis B:
39.2% of U.S. Newborns Aren't Getting Hepatitis B Vaccine at Birth
Researchers Suggest Banning or Restricting Lamivudine to Avoid Drug Resistance
Knowledge Gap About Hepatitis B Persists Among Asian-Americans
Even Liver Specialists Fail to Immunize Patients Against Viral Hepatitis
Many Seek Viral Hepatitis Tests Only When Symptoms Appear
After Six Years of Tenofovir Treatment, Still No Signs of Drug Resistance
More Studies Examine Link Between Vitamin D and Liver Damage
Study Examines Which Hepatitis B Patients Relapse with Chemotherapy
Interferon Treatment May Cause Some Hearing Loss
African-Americans Suffer the Highest Rates of New HBV Infections in the U.S.
3. John's Story: "Lemons to Lemonade"!
John relates his story and how the diagnosis and treatment changed his life in this inspiring story of overcoming the odds.
4. Affordable Care Act (ACA):
Exchanges Prepare to Open
The Health Exchange marketplaces under the Affordable Care Act are being set up now. This is where you will be able to purchase health insurance regardless of your medical condition or health history. By Jacques Chambers, CLU. Click Here.
5. Updated HCV Training Workshop Schedule!
6. Clinical Trials Postings: Updated—August 12!
Be sure to check out the latest clinical trial postings at the HCV Advocate News & Pipeline Blog. Just click on the links to the Drug Companies at the top and to see which drugs are in trials right now, where the trials are, and how to register for one.
Don’t forget that there is help as close as a phone call – the 877-HELP-4-HEP line (877-435-7443) is available 9:00am to 7:00pm Eastern Time. For more information about the services they offer either call or visit their Website at www.help4hep.org The helpline is run by The Support Partnership: a group of non-profits working together to help people affected by hepatitis C.
7. Top News (Blog) from the HCV Advocate News & Pipeline Blog includes:
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org
**Questions and Comments: Questions and/or comments can be directed to email@example.com
**To receive the eblast in your email inbox simply send an e-mail to: firstname.lastname@example.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.
Follow us on Twitter